Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Bruner

Allergy & Immunology Clinton Twp, MI Doctor of Osteopathy

NPI 1215955422 CMS profile 100930

42607 Garfield Rd, Clinton Twp, MI 48038

Open in the dashboard

General payments

$18,450

735 records reported · program years 2019–2025

Research payments

$233

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$19,166 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jeffrey Bruner of Clinton Twp, MI is reported in the CMS Open Payments database as having received $18,450 across 735 general payments and $233 in research payments paid to them. Separately, studies naming them as principal investigator received $19,166 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,277 108
2024 General $2,806 118
2023 General $2,011 103
2022 General $2,744 131
2021 General $2,211 107
2020 General $1,228 77
2019 General $5,172 91
2019 Research $233 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Bruner
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jeffrey Bruner were reported at $2,277. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Jeffrey Bruner Allergy & Immunology median Middle half National median
2019 $5,172 $594 $163–$1,512 $163
2020 $1,228 $426 $106–$1,233 $114
2021 $2,211 $638 $157–$1,708 $132
2022 $2,744 $790 $205–$1,961 $149
2023 $2,011 $852 $220–$2,147 $160
2024 $2,806 $865 $203–$2,267 $164
2025 $2,277 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $6,805 158 payments
  2. GlaxoSmithKline, LLC. $1,797 137 payments
  3. Genzyme Corporation $1,567 50 payments
  4. Regeneron Healthcare Solutions, Inc. $1,276 59 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $1,066 38 payments
  6. ALK-Abello, Inc $811 35 payments
  7. CSL Behring $732 34 payments
  8. Amgen Inc. $724 43 payments
  9. Novartis Pharmaceuticals Corporation $679 31 payments
  10. Teva Pharmaceuticals USA, Inc. $501 25 payments
  11. Other $2,491 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,463 725 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,650 2 payments
  3. Travel and Lodging $826 3 payments
  4. Consulting Fee $360 1 payment
  5. Education $151 4 payments
Products named General payments · program years 2019–2025
  1. DALIRESP $3,186 5 payments
  2. DUPIXENT Immunology $1,962 68 payments
  3. FASENRA $1,416 43 payments
  4. DUPIXENT Inflammation And Immunology $1,170 55 payments
  5. Odactra $795 34 payments
  6. BREZTRI $773 33 payments
  7. NUCALA $771 52 payments
  8. TRELEGY ELLIPTA $763 63 payments
  9. TEZSPIRE Inflammation $677 41 payments
  10. TEZSPIRE Respiratory $644 18 payments
  11. Other $8,871 427 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $233 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,482

Median for Allergy/ Immunology: 449

Drug cost

$930,549

Median for Allergy/ Immunology: $169,700

Branded share of claims

49%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 228 $260,346
Dupixent Pen Dupilumab Brand 50 $181,803
Spiriva Respimat Tiotropium Bromide Brand 117 $126,672
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 56 $58,708
Breo Ellipta Fluticasone/Vilanterol Brand 79 $51,885
Arnuity Ellipta Fluticasone Furoate Brand 84 $34,855
Qvar Redihaler Beclomethasone Dipropionate Brand 80 $34,275
Dulera Mometasone/Formoterol Brand 28 $21,518
Advair Hfa Fluticasone Propion/Salmeterol Brand 46 $21,065
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 43 $20,523

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$111,271

Of which drugs: $1,040

Medicare patients

208

Average age 72

Services billed

8,267

147 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 49%
COPD 26%
Diabetes 25%
Ischemic heart disease 23%
Chronic kidney disease 20%
Depression 17%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 13 13 $954

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$797 50 —
TEZSPIRE
$383 — —
XOLAIR
$333 — —
AIRSUPRA
$232 — —
NUCALA
$185 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

736 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record